Design of tethered antimicrobial peptides for permanent medical device coatings.

用于永久性医疗器械涂层的束缚抗菌肽的设计。

• 批准号: 7404826
• 负责人: Christopher Loose
• 金额: $ 9.99万
• 依托单位: SEMPRUS BIOSCIENCES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-15 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7404826
• 关键词: Address; Adhesions; Amines; Antibiotics; Area; Award; Bacteria; Bioinformatics; Biological Assay; Blood; Businesses; Catheters; Cells; Class; Classification; Clinical; Communities; Construction Materials; Contracts; Coupled; Custom; Databases; Development; Devices; Diffuse; Drug resistance; Emerging Technologies; Engineering; Erythrocytes; Escherichia coli; Ethylene Glycols; Generations; Goals; Gram-Negative Bacteria; Head; Histamine Release; Hospitals; Hour; Human; Hybrids; In Situ; In Vitro; Incidence; Infection; Infection prevention; Ions; Knowledge; Lead; Length; Licensing; Longevity; Manufacturer Name; Medical Device; Membrane; Metals; Methodology; Methods; Microbial Biofilms; Modification; Natural Resistance; Nature; Pattern; Peptide Synthesis; Peptides; Phase; Plant Resins; Pliability; Polymers; Polyurethanes; Prevention; Procedures; Process; Proteins; Pseudomonas aeruginosa; Range; Research; Research Personnel; Resistance; Serum; Shapes; Silicones; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; Solvents; Staphylococcus aureus; Sterilization for infection control; Stream; Structure; Surface; Technology; Temperature; Testing; Time; Toxic effect; Universities; Venous; Work; antimicrobial; antimicrobial drug; antimicrobial peptide; bacterial resistance; base; biomaterial compatibility; cecropin; clinically relevant; computerized tools; cost; cytotoxic; cytotoxicity; design; ethylene glycol; experience; immunogenicity; in vivo; killings; nanoscale; novel; prevent; resistance mechanism; size; success; tool

DESCRIPTION (provided by applicant): Widespread infections related to the use of medical devices have highlighted the inherent vulnerability of hospital procedures to bacterial invasion. In order to battle these costly and potentially deadly infections, a variety of second-generation devices, such as antimicrobial central venous catheters (CVCs), have been engineered to incorporate slow-release antibiotics or metal ions onto the device surface. Although many of these antimicrobial products have come into use, they have limited efficacy and an insufficient lifespan for many applications. In addition, clinicians have been hesitant to use devices with coatings that release antimicrobial agents into the blood stream due to concerns over systemic toxicity and the development of drug resistance. In order to address the remaining clinical need for antimicrobial medical devices, SteriCoat founders have been developing permanent antimicrobial coatings that may be applied to a wide range of medical devices. The novelty and commercial potential of our technology has been recognized throughout the entrepreneurial community through awards such as first place in both the MIT 100K and the Oxford University business plan competitions. Our process of permanently attaching custom-designed, broad- spectrum antimicrobial peptides (AmPs) to versatile coatings will enable us to overcome the inherent scientific limitations of existing slow-release coatings such as limited long-term efficacy, systemic toxicity, and the development of bacterial resistance. In this application, SteriCoat is designing optimized agents for permanent coatings to prevent the infection of medical devices of any size, shape or material. This coating will overcome the inherent scientific limitations of existing slow-release technologies.

描述(由申请人提供)：与使用医疗器械有关的广泛感染突出了医院程序对细菌入侵的固有脆弱性。为了对抗这些昂贵且可能致命的感染，各种第二代设备，如抗菌中心静脉导管(CVCs)，已经被设计成将缓释抗生素或金属离子结合到设备表面。虽然这些抗菌产品中有许多已经投入使用，但它们的疗效有限，许多应用的寿命不足。此外，由于担心全身毒性和耐药性的发展，临床医生一直在犹豫是否使用带有涂层的设备将抗菌剂释放到血流中。 为了满足临床上对抗菌医疗设备的剩余需求，SteriCoat的创始人一直在开发可应用于各种医疗设备的永久性抗菌涂层。我们的技术的新颖性和商业潜力已经通过诸如麻省理工学院100K和牛津大学商业计划竞赛的第一名等奖项在整个企业家社区得到了认可。我们将定制的广谱抗菌肽(AMPS)永久附着在多功能涂料上的工艺将使我们能够克服现有缓释涂料固有的科学局限性，如有限的长期疗效、全身毒性和细菌耐药性的发展。 在这一应用中，SteriCoat正在为永久涂层设计优化的试剂，以防止任何大小、形状或材料的医疗器械受到感染。这种包衣将克服现有缓释技术固有的科学局限性。